Alembic Pharmaceuticals receives USFDA approval for generic cancer treatment Nelarabine Injection.

Alembic Pharmaceuticals receives final USFDA approval for its generic cancer treatment, Nelarabine Injection, equivalent to Sandoz's Arranon Injection. The drug treats T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adults and children aged 1 year and older. The market size for Nelarabine Injection is estimated at $23M for the year ending March 2024. Alembic now has 211 USFDA-approved abbreviated new drug applications (ANDAs).

August 02, 2024
3 Articles